N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Phase 4 N=30 Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
Arrhythmia · Atrial Fibrillation · Atrial Flutter
Primary: Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose. — 0.20 Correlation coefficient R
N/A N=5,060 Drug-Targeted Alerts for Acute Kidney Injury
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
Phase 1 N=30 Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Liver Cancer
Primary: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized) — 2.67; 3.68; 7.11; 0.08 ng/mL/mg — p=.036
Phase 2 N=26 Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
HIV/AIDS · Antiviral Toxicity · Antiviral Drug Adverse Reaction
Primary: Change in Mitochondrial Function [Cellular Oxygen Consumption (COC)] Over 12 Months After Switch of Antiretrovirals. — 50; 70 pmoles O2/min — p=<0.001
Phase 2 N=36 In Vivo Assessment of Silver Biomaterial Nano-Toxicity
Healthy
Primary: Change in Sodium Blood Levels — -0.1; 0.2 mmol/L
Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
N/A N=135 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
N/A N=274 Pathogenesis of Adverse Drug Reactions
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Phase 4 N=21 Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
Acetaminophen Toxicity
Primary: Rise in Plasma Transaminases: Proportion of Responders. — 6; 8 Participants — p=0.59
Phase 4 N=19 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
Anticholinergics Toxicity
Primary: Comparison of RASS Score Between Physostigmine and Lorazepam: Before Bolus — 1.5; 1 score on a scale
Phase 4 N=132 Renal Safety Evaluation After Dotarem®-Enhanced MRI
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
Phase 2 N=66 Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
Healthy Volunteers · Brain Lesion
Primary: Pharmacokinetic (PK) Parameter Cmax — 248.7; 524.5; 698.7; 992.0 µg/mL
N/A N=67 Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol
Liver Dysfunction
Primary: Changes in the M30 and M65 Markers Related to the Anesthesia Type — 237.27; 279.97; 427.33; 470.30 U/L
Phase 2 N=93 Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
Reperfusion Injury
Primary: Peak Aspartate Aminotransferase Within First 72h Post Transplant — 1262.9; 1451.2 U/L
N/A N=15 Effect on Acetaminophen Metabolism by Liquid Formulations
Acetaminophen Metabolism · Acetaminophen Poisoning · Drug Metabolism by Excipients
Primary: Acetaminophen Metabolites — 2.411; 2.009 mcg.hr/ml
Phase 1 N=4 Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
Parkinson Disease
Primary: Maximum Plasma Concentration (Cmax) — 482.98 ng-eq/mL
N/A N=312 Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
Cancer
Primary: Rate of Severe Toxicity — 14; 75; 43 Participants
Phase 1 N=18 Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Sepsis · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Number of Participants With Adverse Events — 3; 4; 5; 4 Participants
Phase 1 N=6 Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2
Healthy Volunteers
Primary: Absolute Bioavailability of PBT2 (F%) — 15.936 percentage of absolute bioavailability
Phase 1 N=38 Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
Healthy
Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale
N/A N=513 Comparison of Contrast Agents During CT Angiography
Contrast Enhancement on Cardiac CT
Primary: Image Quality of the CT Scans Using Different Contrast Agents — 333; 357; 362; 288 hounsfield units
Phase 2 N=47 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Phase 4 N=49 Kidney Damage in Patients With Normal eGFR
Coronary Artery Stenosis
Primary: Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media. — -14.84; -17.71; -9.98; -2.37 ng/mL
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
Phase 4 N=30 Envarsus Neurotoxicity Burden in Liver Transplant Patients
Neurotoxicity · Liver Transplant; Complications
Primary: Change in Neurotoxicity Burden — -5; -4 score on a scale
N/A N=451 Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants